Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Merck Defends Right Not To Publish Clinical Trials

This article was originally published in The Pink Sheet Daily

Executive Summary

Merck believes clinical trial disclosure rules must distinguish between hypothesis-generating and hypothesis-testing trials.

You may also be interested in...



Medical Journals To Require Registration Of All Controlled Trials On ClinicalTrials.gov

The International Committee of Medical Journal Editors will require that studies be registered at or before patient enrollment in order to be considered for publication. A Sept. 9 editorial notes that only ClinicalTrials.gov currently fits ICMJE registry criteria.

Medical Journals To Require Registration Of All Controlled Trials On ClinicalTrials.gov

The International Committee of Medical Journal Editors will require that studies be registered at or before patient enrollment in order to be considered for publication. A Sept. 9 editorial notes that only ClinicalTrials.gov currently fits ICMJE registry criteria.

Medical Journals To Propose Making Trial Registry Condition For Publication

International Committee of Medical Journal Editors will publish an editorial Sept. 9 proposing to make clinical trial registration a prerequisite for later publication. Merck exec highlights concerns with “assumption of...surreptitious behavior” that is behind the proposal.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS060736

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel